Alphamab Oncology Wins CDE Approval for Phase II JSKN033 Cervical Cancer Trial

Reuters2025-12-29

Alphamab Oncology Wins CDE Approval for Phase II JSKN033 Cervical Cancer Trial

Alphamab Oncology announced that its Investigational New Drug $(IND)$ application for a phase II clinical trial of JSKN033 has been officially accepted by the Center for Drug Evaluation $(CDE)$. The trial will evaluate JSKN033, a high-concentration subcutaneous co-formulation of an anti-HER2 bispecific antibody-drug conjugate and a PD-L1 immune checkpoint inhibitor, in combination with platinum-based chemotherapy with or without bevacizumab as a first-line treatment for advanced cervical cancer. The company cautioned that successful development or marketing of JSKN033 is not guaranteed. No other beneficiary organizations were mentioned.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Alphamab Oncology published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20251229-11968222), on December 29, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2595798206?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-12-29 12:11","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2595798206","market":"nz","top_or_hot":-1,"title":"Alphamab Oncology Wins CDE Approval for Phase II JSKN033 Cervical Cancer Trial","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Alphamab Oncology Wins CDE Approval for Phase II JSKN033 Cervical Cancer Trial\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Alphamab Oncology announced that its Investigational New Drug <a href=\"https://laohu8.com/S/IND\">$(IND)$</a> application for a phase II clinical trial of JSKN033 has been officially accepted by the Center for Drug Evaluation <a href=\"https://laohu8.com/S/CDE\">$(CDE)$</a>. The trial will evaluate JSKN033, a high-concentration subcutaneous co-formulation of an anti-HER2 bispecific antibody-drug conjugate and a PD-L1 immune checkpoint inhibitor, in combination with platinum-based chemotherapy with or without bevacizumab as a first-line treatment for advanced cervical cancer. The company cautioned that successful development or marketing of JSKN033 is not guaranteed. No other beneficiary organizations were mentioned.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Alphamab Oncology published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20251229-11968222), on December 29, 2025, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Alphamab Oncology Wins CDE Approval for Phase II JSKN033 Cervical Cancer Trial</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAlphamab Oncology Wins CDE Approval for Phase II JSKN033 Cervical Cancer Trial\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-12-29 12:11</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Alphamab Oncology Wins CDE Approval for Phase II JSKN033 Cervical Cancer Trial\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Alphamab Oncology announced that its Investigational New Drug <a href=\"https://laohu8.com/S/IND\">$(IND)$</a> application for a phase II clinical trial of JSKN033 has been officially accepted by the Center for Drug Evaluation <a href=\"https://laohu8.com/S/CDE\">$(CDE)$</a>. The trial will evaluate JSKN033, a high-concentration subcutaneous co-formulation of an anti-HER2 bispecific antibody-drug conjugate and a PD-L1 immune checkpoint inhibitor, in combination with platinum-based chemotherapy with or without bevacizumab as a first-line treatment for advanced cervical cancer. The company cautioned that successful development or marketing of JSKN033 is not guaranteed. No other beneficiary organizations were mentioned.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Alphamab Oncology published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20251229-11968222), on December 29, 2025, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1574","symbol_name":"生物医药B类股","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251229:nNDL3VT9Lk:1","article_id":"2595798206","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2595798206","pubTimestamp":1766981500,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Alphamab Oncology announced that its Investigational New Drug  application for a phase II clinical trial of JSKN033 has been officially accepted by the Center for Drug Evaluation . The trial will evaluate JSKN033, a high-concentration subcutaneous co-formulation of an anti-HER2 bispecific antibody-drug conjugate and a PD-L1 immune checkpoint inhibitor, in combination with platinum-based chemotherapy with or without bevacizumab as a first-line treatment for advanced cervical cancer. The company cautioned that successful development or marketing of JSKN033 is not guaranteed. No other beneficiary organizations were mentioned.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Alphamab Oncology published the original content used to generate t","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK1574":"生物医药B类股","09966":"康宁杰瑞制药-B","BK1161":"生物科技"},"translate_title":"康宁杰瑞肿瘤学JSKN033宫颈癌II期试验获CDE批准","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"09966":0.9},"content_text":"Alphamab Oncology Wins CDE Approval for Phase II JSKN033 Cervical Cancer Trial\n    \n\n        Alphamab Oncology announced that its Investigational New Drug $(IND)$ application for a phase II clinical trial of JSKN033 has been officially accepted by the Center for Drug Evaluation $(CDE)$. The trial will evaluate JSKN033, a high-concentration subcutaneous co-formulation of an anti-HER2 bispecific antibody-drug conjugate and a PD-L1 immune checkpoint inhibitor, in combination with platinum-based chemotherapy with or without bevacizumab as a first-line treatment for advanced cervical cancer. The company cautioned that successful development or marketing of JSKN033 is not guaranteed. No other beneficiary organizations were mentioned.\n      \n\n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Alphamab Oncology published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20251229-11968222), on December 29, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2595798206","isCrawlerRequest":true}